{"url_path":"/sec/revb/8-k/2026-07-13/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-13","source_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-302008-index.html","accession_number":"0001193125-26-302008","cik":"0001810560","ticker":"REVB","issuer_name":"REVELATION BIOSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810560/0001193125-26-302008-index.html","primary_entity_key":"0001810560","primary_entity_name":"REVELATION BIOSCIENCES, INC."},"word_count":123,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\n \n\nOn July 10, 2026, the Company issued a press release announcing the adoption of the Rights Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\n \n\nThe information in this Item 7.01, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."}